Role of brain neuroactive steroids in the functional interplay between the GABA(A) and the NPY-Y1 receptor mediated signals in the amygdala by EVA, Carola Eugenia et al.
ehavior 84 (2006) 568–580
www.elsevier.com/locate/pharmbiochembehPharmacology, Biochemistry and BRole of brain neuroactive steroids in the functional interplay between the
GABAA and the NPY-Y1 receptor mediated signals in the amygdala
Carola Eva a,⁎, Alessandra Oberto a, Paolo Mele a, Mariangela Serra b, Giovanni Biggio b
a Dipartimento di Anatomia, Farmacologia e Medicina Legale, Sezione di Farmacologia, Via Pietro Giuria 13, 10125, Università di Torino, Torino, Italy
b Dipartimento di Biologia Sperimentale, Sezione di Neuroscienze, Università di Cagliari, Cagliari, Italy
Available online 5 July 2006Abstract
Various lines of evidence suggest a functional interaction between GABAA and Neuropeptide Y (NPY)-Y1 receptor (Y1R) mediated
transmissions in various brain regions, which can be important in the regulation of sedation, feeding, anxious behaviour and neuronal excitability.
By using a transgenic mouse model carrying the murine Y1R gene promoter fused to the lacZ reporter gene (Y1R/LacZ mice), we showed that
prolonged pharmacologically or physiologically induced changes in the cerebrocortical concentrations of the neuroactive steroids 3alpha-hydroxy-
5alpha-pregnan- 20-one (3alpha,5alpha TH PROG) and tetrahydrodeoxycorticosterone (3alpha,5alpha TH DOC) increases Y1R/LacZ transgene
expression in the central and medial amygdala, an effect similar to that induced by long-term treatment with positive modulators of the GABAA
receptor complex (diazepam or abecarnil). We also demonstrated that fluctuations in the cerebrocortical concentrations of 3alpha,5alpha-TH
PROG and 3alpha,5alpha TH DOC during voluntary ethanol consumption and ethanol withdrawal induces a marked increase in Y1R gene
expression that becomes apparent 48 h after withdrawal.
These data provide evidence that neuroactive steroids may play an important role in the functional interaction between the GABAA receptor
and NPY-Y1R mediated pathways in the amygdala, which might represent an important regulatory mechanism for modulation of several functions,
including ethanol withdrawal.
© 2006 Elsevier Inc. All rights reserved.Keywords: GABA; Neuroactive steroids; Neuropeptide Y; Y1 receptors; Pregnancy; Ethanol; Stress; Amygdala; Transgenic mice1. Introduction
Neuropeptide Y (NPY)1 is one of the most abundant and
widely distributed peptides in the central nervous system that
belongs, together with the peptide YY (PYY) and the pancreatic
polypeptide (PP), to the family of pancreatic peptides (Tatemoto
et al., 1982). Immunohistochemical and in situ hybridization
studies have shown that NPY is abundantly expressed in various
brain regions of rodents and humans, including the cerebral cor-
tex, amygdala, hypothalamus, hippocampus, locus coeruleus and
nucleus accumbens (Allen et al., 1983; Chronwall et al., 1985; deAbbreviations:NPY, neuropeptideY;Y1R,Y1 receptor; GABA,γ-aminobutyric
acid; GABAA, GABA type A receptor; 3alpha,5alpha TH PROG, 3alpha-hydroxy-
5alpha-pregnan-20-one; 3alpha,5alpha TH DOC, tetrahydrodeoxycorticosterone;
MeA, medial amygdala; CeA, central amygdala; ARC, arcuate nucleus; PVN,
paraventricular nucleus; IR, immunoreactive.
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doi:10.1016/j.pbb.2006.05.014Quidt and Emson, 1986; Dumont et al., 1992; Chronwall and
Zukowska, 2004). In the brain, NPYparticipates in the regulation
of several physiological functions that include emotional be-
haviour and stress response, neuronal excitability, feeding behav-
iour and energy homeostasis, ethanol consumption, learning and
memory, GnRH secretion, sexual behaviour and circadian rhy-
thms (Kalra and Crowley, 1992; Wahlestedt and Reis, 1993;
Colmers and Bleakman, 1994; Baraban et al., 1997; Hokfelt et al.,
1998; Vezzani et al., 1999).
NPY interacts with at least five different G-protein coupled
receptors named Y1, Y2, Y4, Y5, and y6 subtypes (Blomqvist and
Herzog, 1997; Michel et al., 1998). The Y1 receptor (Y1R), Y2
receptor and Y5 receptor bind preferentially to NPY and PYY
whereas PP is the preferring ligand for the Y4 receptor. (Lundell
et al., 1995; Rose et al., 1995; Gerald et al., 1996; Weinberg et al.,
1996). Since the y6 receptor protein is truncated in most mammals
and it is functional only in mouse and rabbit, its biological rel-
evance remains to be clarified (Starback et al., 2000).
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cloned in the rat by us (Eva et al., 1990; Krause et al., 1992) and
subsequently in human (Herzog et al., 1992) andmouse (Eva et al.,
1992). Sequence analysis of mammalian and non-mammalian
Y1Rdemonstrated that it displays a high sequence homology in the
transmembrane regions and it is highly conserved throughout
evolution (Larhammar and Salaneck, 2004). Y1R is coupled to the
inhibition of adenylate cyclase, by the activation of a pertussis
toxin sensitiveGTP binding protein Gi/Go, and to themobilization
of Ca+2 from intracellular stores (Herzog et al., 1992). Moreover,
Y1R stimulates the mitogen activated protein kinase (MAPK)
pathways, via extracellularly regulated kinase (ERK) phosphory-
lation, an effect that has been shown to be dependent on PI-3-
kinase (Nie and Selbie, 1998; Mannon and Mele, 2000).
The distribution of Y1R within the mammalian CNS was
extensively analyzed using receptor autoradiography, immuno-
histochemistry and in situ hybridization. By using receptor
autoradiography Y1R-binding sites were found in the cerebral
cortex, olfactory nuclei, dentate gyrus, thalamus, septum, cere-
bellum and in the paraventricular (PVN) and dorsomedial hypo-
thalamic nuclei (Dumont et al., 1998). More recent studies in rat
andmouse, using specific cRNA probes and in situ hybridization
techniques, detected a larger amount of Y1R mRNA positive
neurons, in particular in the thalamus, in the limbic system
(hippocampus, amygdala and bed nucleus of the stria terminalis)
and in the hypothalamus (medial preoptic area, PVN, dorsome-
dial, ventromedial and arcuate (ARC) hypothalamic nuclei)
(Kishi et al., 2005). The lack of localization of Y1R mRNAwith
NPY mRNA observed in the human brain suggests that the Y1R
is mainly located postsynaptically (Caberlotto et al., 2000).
However the presence of Y1R has been identified in NPY-IR
neurons in the nucleus accumbens, medial amygdala (MeA) and
rat hippocampus suggesting that the Y1R may also act as a
presynaptic receptor (St-Pierre et al., 1998, 2000; Pickel et al.,
1998; Oberto et al., 2001).
The physiological importance of the Y1R was first discovered
by pharmacological studies using selective agonists and anta-
gonists showing high binding affinities for this receptor subtype.
The functional contributions of Y1R to a particular physiological
process have also been provided by studies on genetically
modified mice lacking the Y1R subtype (Pedrazzini et al., 1998;
Kushi et al., 1998; Kanatani et al., 2000; Naveilhan et al., 2001b;
Howell et al., 2003) as well as by studies showing dynamic
changes of this receptor subtype in response to different con-
ditions, for instance stress and anxiety, convulsions or changes in
feeding behaviour (Eva et al., submitted for publication).
In the brain, theY1R subtype has been involved in several NPY-
induced responses, such as the anxiolytic effects and stress
response (Broqua et al., 1995; Heilig, 1995; Sajdyk et al., 2004),
ethanol drinking behaviour (Thiele et al., 2002; Schroeder et al.,
2003; Thiele and Badia-Elder, 2003; Sparta et al., 2004), stim-
ulation of food intake (Kask et al., 1998; Kanatani et al., 2000;
Wisialowski et al., 2000; Mullins et al., 2001) and activation of
neuroendocrine axis (Kalra et al., 1992; Besecke et al., 1994).
Moreover, different lines of evidence have shown that Y1R plays a
permissive role in seizures (Gariboldi et al., 1998; Vezzani et al.,
2000, 2002; Benmaamar et al., 2003).2. NPY and γ-aminobutyric acid (GABA)
NPY has similar properties to those observed with positive
modulators of the GABA type A (GABAA) receptor complex,
like benzodiazepines and neuroactive steroids, on sleep (Heilig
and Murison, 1987; Yamada et al., 1996; Ehlers et al., 1997),
anxiety, stress (Heilig et al., 1989, 1992; Broqua et al., 1995;
Sajdyk et al., 1999; Bannon et al., 2000; Thorsell et al., 2000;
Kask et al., 2001), convulsions (Mikkelsen et al., 1994; Erickson
et al., 1996; Baraban et al., 1997; Woldbye et al., 1997; Bolwig
et al., 1999), as well as feeding behaviour (Cowley et al., 2001;
Pronchuk et al., 2002; cuna-Goycolea et al., 2005; Sato et al.,
2005). Various lines of evidence suggest a functional interaction
between GABA and NPY that can be important in the regulation
of sedation, feeding, anxious behaviour and neuronal excitability
(Kask et al., 1996; Oberto et al., 2000, 2002; Ferrara et al., 2001;
Mikkelsen et al., 2001; Ovesjo et al., 2001; Zhang and Wang,
2005). For instance, GABA is coexpressed with NPY/Agouti-
Related Protein in ARC neurons (Horvath et al., 1997; Pu et al.,
1999) projecting into the PVN where they act synergistically to
inhibit Corticotropin Releasing Factor neurons and to enhance
feeding (Hahn et al., 1998; Broberger et al., 1998a,b; Pu et al.,
1999). Moreover GABA is co-released from NPY/Agouti-
Related Protein neurons in the ARC were it was shown to inhibit
Proopiomelanocortin neurons by acting through different recep-
tors (Horvath et al., 1997; Pu et al., 1999; Cowley et al., 2001).
Anatomical and functional evidence also suggests an interplay
between hypothalamic GABAergic neurons and NPY (Pu et al.,
1999; Cowley et al., 2001; Horvath et al., 2001; Pronchuk et al.,
2002) in the regulation of both fertility and food intake (Kalra
et al., 1991; Catzeflis et al., 1993; Glass et al., 1999; Raposinho
et al., 2001). In particular, NPY has been suggested to inhibit
fertility by decreasing the activity of GABAergic neurons afferent
to Gonadotropin Releasing Hormone neurons, an effect that
appears to be mediated via the NPY-Y1R subtype (Sullivan and
Moenter, 2004).
In the hippocampus and neocortex, NPY is made by neurons
that almost all express GABA (Pu et al., 1999; Jinno andKosaka,
2003). Results from several studies have indicated that neo-
cortical and hippocampal neurons coexpressing NPY and
GABA might be involved in the response to epileptogenesis.
In the neocortex, NPY was found to increase GABAergic neu-
rotransmission onto pyramidal neurons and to decrease in-
hibition on GABAergic interneurons (Bacci et al., 2002). Each
of these NPY actions decreases excitability in cortical circuits,
resulting in the potentiation of NPY and GABA inhibitory
responses. NPY/GABA interneurons in the hippocampus are
selectively ablated in rat epilepsy models in vivo (Sloviter, 1989,
1991) and in epileptic patients (de Lanerolle et al., 1989).
A functional interaction between the GABAergic and NPY-
Y1R mediated transmissions in the regulation of emotional
behaviour was first demonstrated by Kask et al. (1996) that
showed that the anxiolytic benzodiazepine diazepam blocks the
anxiogenic effect of Y1R antagonists. NPY was also reported to
induce sedative effects through the GABAergic system by
interacting with the Y1R in the posterior hypothalamus (Naveil-
han et al., 2001a).
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induces changes in the expression of NPY and NPY mRNA in
various brain region. Acute, sub-chronic and chronic treatments
with benzodiazepines affects the NPY immunoreactivity in the
amygdala, cerebral cortex and locus coeruleus and hypothalamus
in naive rats (Krysiak et al., 1999) and in ratswith conditioned fear
produced in the passive avoidance test (Krysiak et al., 2000),
although these changes were dependent on the type of treatment
and on the different brain nuclei. In addition, long-term treatment
with flurazepam induces a decrease of NPY immunoreactivity in
the hippocampus of tolerant and dependent rats that is associated
with the decrease of Y1R mRNA expression in tolerant rats but
not during withdrawal (Zhang and Wang, 2005).
Moreover, intrahippocampal administration of antisense
oligonucleotides against the GABAA receptor γ2 subunit, that
induces spontaneous electrographic hippocampal seizures and
elevates seizure threshold induced by electrical stimulation,
increases NPY mRNA and receptor protein in the hippocampal
region. (Mikkelsen et al., 2001). This induction of NPY has
been suggested to be a part of compensatory mechanism acting
in response to a reduction in functional hippocampal postsyn-
aptic GABAA receptors.
By using a Y1R/LacZ transgenic mouse model, we exten-
sively investigated the functional interaction between GABAer-
gic and NPY-Y1R mediated transmission in the amygdala. We
here summarize the results of several studies from our laboratory
suggesting that changes in GABAA receptor function, induced
by various pharmacological and physiological conditions, may
affect NPY-Y1R signal transmission by modulating the gene
expression of the Y1R subtype in the MeA and in the central
amygdala (CeA).
3. The Y1R/LacZ transgenic mouse model
We generated a transgenic mouse line (Y1R/LacZ mice)
bearing the 1.3 Kb 5′ flanking region of the murineY1R gene
promoter linked to the coding region of the Escherichia coli
LacZ gene (Oberto et al., 1998). Analysis of Y1R/LacZ transgene
activity by histochemical staining of β-galactosidase with X-gal
demonstrated that this construct contains sufficient information
to replicate the expression pattern of the endogenous Y1R gene
in a CNS-restricted and developmental stage-specific manner.
Four transgenic lines showed characteristic patterns of β-galac-
tosidase activity in specific brain regions; moreover, the onto-
genetic analysis indicated that the transgenic construct appears
to be activated with the same timing of the endogenous Y1R
during the development of the embryonic nervous system.
The advantages of this transgenic model are that β-galac-
tosidase staining with chromogenic substrate X-gal is more sen-
sitive and more readily quantifiable than mRNA in situ
hybridization and it can be usefully employed to quantitatively
evaluate in vivo changes in transgene expression.
To study in vivo the regulation of Y1R gene expression at the
transcriptional level we employed computer-assisted morpho-
metrical techniques to quantitatively evaluate changes in Y1R/
LacZ transgene expression by automatically quantifying the
number of dye precipitates within a selected region, (Russ,1995). These calculations allow a numerical measurement which
is proportional to the histochemical activity of the expressed
transgene and are extremely useful for statistical comparison of
different treatments.
By using this approach, we have shown that chronic modu-
lation of GABAA receptor function regulates Y1R gene
expression in the amygdala of Y1R/LacZ transgenic mice.
Furthermore we demonstrated that Y1R/LacZ transgene expres-
sion in the CeA and MeA can be also modulated in response to a
long-lasting increase in the cerebrocortical concentrations of
neuroactive steroids induced by various pharmacological and
physiological conditions.
4. Morphological evidence of a functional interplay
between the GABAergic and NPY-Y1R systems in the MeA
Using immunolabelling for NPY and GABA and histochem-
ical staining of Y1R/LacZ transgene expression we provided
morphological evidence for a functional interaction between
GABA and NPY-Y1R mediated transmission in the MeA (Fig. 1)
(Oberto et al., 2001). The confocal analysis of GABA and NPY-
immunoreactive (IR) neurons in brain coronal sections from Y1R/
LacZ transgenic mice has shown that in the MeA the majority of
NPY-IR cell bodies were positive for GABA and that, in some
cases, GABA and NPY coexist within the same nerve fibers.
Moreover, the simultaneous detection of β-galactosidase histo-
chemical staining and of GABA and NPY immunostaining
revealed a high degree of colocalization for GABA or NPY and
the Y1R/LacZ transgene. GABA-IR neurons coexpressing β-
galactosidase histochemical staining were usually in close contact
with NPY-IR fibers that were surrounding or covering the cell
bodies, suggesting that NPY neurons innervate GABAergic neu-
rons that also express the Y1R gene and that NPY might inhibit
GABA release by the activation of this receptor subtype. Few
NPY-IR cell bodies also showed the β-galactosidase histochem-
ical staining suggesting that the Y1R may also act as an auto-
receptor in this brain area. On the other hand, several GABA-IR
elements, that do not display β-galactosidase positive staining,
are surrounded by NPY positive fibers, indicating that not all
GABAergic neurons are regulated by Y1R. These findings could
account for a complex response to NPY in the MeA and suggest
that the interconnectivity between the NPY-Y1R-mediated
transmission and the GABAergic system may be an important
regulatory mechanism within the MeA and may contribute to the
effects of NPYon anxious behaviour.
5. Chronic modulation of GABAA receptor function
regulates Y1R gene expression in the amygdala
To provide functional evidence for interplay between GABA
and NPY systems within the amygdala we first analyzed the
effect of modulation of GABAA receptor complex on Y1R gene
expression in the MeA of Y1R/LacZ transgenic mice.
Positive allosteric modulators of GABA receptor complex,
such benzodiazepines, enhance GABAA receptor function and
produce sedative, anxiolytic and anticonvulsant effects on be-
haviour (Costa et al., 1975; Haefely, 1986; Costa and Guidotti,
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receptor complex, such as β-carbolines FG 7142, inhibit GABA-
gated Cl-channels and elicit anxiogenic and proconvulsant
activity (Dorow et al., 1983). Chronic administration of diazepam
and other agonists of the benzodiazepine binding site decreases
GABAA receptor function whereas repeated administration of β-
carbolines increases sensitivity to its proconvulsant activity
(Corda et al., 1985; Woods et al., 1992). These behavioural andFig. 1. Confocal images illustrating the coexistence and close relationships among NP
NPY, in red the immunolabelling for GABA, in dark blue the histochemical staining
GABA (red) coexist. A–F: confocal images obtained merging several focus planes.
represents 30 μm. In A and C, the arrow points to the same fiber recognisable for its ch
fiber is stained in yellow in B. In D and F the arrows point to numerous co-existent NP
arrowheads indicate a few of the numerous elements showing also the histochemica
showing also β-galactosidase activity. The asterisk indicates one yellow cell body pos
image reconstructed from the series to which H is belonging. Reprinted fromOberto et
interpretation of the references to colour in this figure legend, the reader is referred tphysiological effects are associated with changes in the expres-
sion of GABAA receptor subunits mRNA (Chen et al., 1999).
We demonstrated that the prolonged treatment with positive
(diazepam and abecarnil ) or negative modulators (FG7142) of
GABAA receptor function induces, respectively, a significant
increase, or decrease, of the Y1R gene expression in the MeA.
These findings are consistent with the hypothesis that, in the
amygdala, the NPY-Y1 receptor-mediated transmission andY, GABA, and Y1R/LacZ expressing elements. In green the immunolabeling for
for β-galactosidase. Yellow cells or fibers are elements where NPY (green) and
Bar in A represents 30 μm. G, H: single, not merged confocal images. Bar in G
aracteristic shape showing NPY (A) and GABA (C) immunoreactivity. The same
Y- and GABA-immunoreactive cell bodies which are yellow in E. In G and H the
l staining for β-galactosidase. In H the arrow point to NPY-positive cell bodies
itive for β- galactosidase. The same cell is clearly identifiable in E (asterisk), the
al., Neuropharmacology 2001;41: 639–642, with permission from Elsevier. (For
o the web version of this article.)
Fig. 2. Effects of long-term treatment with progesterone on the concentrations of
progesterone (A), AP (B), and THDOC (C) in the cerebral cortex of Y1R/LacZ
transgenic mice. Mice were treated with vehicle (VEH), progesterone (P), or
progesterone plus finasteride (P+F) according to the 3-week, single-injection,
multiple-withdrawal paradigm, as previously described (Moran and Smith,
1998). They were killed 20 min (P20, P20+F), 90 min (VEH, P90, P90+F), or
24 h (PW, PW+F) after the last injection(W indicates withdrawal), and the
concentrations of 41 progesterone, AP, and THDOC in cerebrocortical
homogenates were determined. Data are means±SEM of values from 3 to
8 mice and are expressed as nanograms of steroid per gram of protein. Pro-
gesterone, *p<0.01 versus VEH, **p<0.05 versus P20; AP, *p<0.05 versus
VEH, **p<0.01 versus P90; THDOC, *p<0.05 versus VEH, P90, PW, and
PW+F (Newman–Keuls test). Reproduced from Ferrara et al., J. Neurochem.
2001;79: 417–425 with permission of Blackwell Publishing.
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GABA may functionally interact in the regulation of anxiety
behaviour (Kask et al., 1996). The molecular mechanisms that
underlie changes in Y1R/LacZ transgene expression induced by
prolonged administration with ligands of the BZ/ω binding site
remain to be determined. Given that the NPY-Y1R mediated
transmission elicits behavioural effects that are indistinguishable
from those induced by the activation of GABAA receptors (Heilig
et al., 1989, 1992; Broqua et al., 1995; Sajdyk et al., 1999; Bannon
et al., 2000; Thorsell et al., 2000; Kask et al., 2001) and that
GABAandNPY coexist within the same neurons in the amygdala
(Gustafson et al., 1986; McDonald and Pearson, 1989; Oberto et
al., 2001), it is possible that changes in the function of GABAA
receptors elicit compensatory responses in the firing rate of
NPYcontaining neurons which, in turn, might be responsible of
changes in Y1 receptor gene transcriptional activity.
6. Role of neuroactive steroids in modulation of NPY-Y1R
transmission in the amygdala
6.1. Effects of a sustained increase in brain concentrations of
neuroactive steroids on Y1R gene expression
The 5-alpha-reducted progesterone (PROG) metabolites,
3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha TH
PROG) and tetrahydrodeoxycorticosterone (3alpha,5alpha TH
DOC), are endogenous neuroactive steroids, which affect the ex-
citability of central neurons in a manner independent of nuclear
hormone receptors (Biggio and Purdy, 2001). These compounds
are among the most potent positive allosteric modulators of the
GABAA receptor complex (Majewska et al., 1986; Belelli and
Lambert, 2005). Thus, their acute administration in pharmacolog-
ical doses potentiate the GABAA receptor function and elicit
anxiolytic, anticonvulsant and hypnotic/anesthetic effects similar to
those produced by other positive allosteric modulators of GABAA
receptors (Lambert et al., 2001; Rupprecht et al., 2001). In
particular, the anxiolytic action of 3alpha,5alpha TH PROG has
been demonstrated in various animal models of anxiety and the
amygdaloid complex has recently been implicated as a brain region
that plays an important role in mediating the anxiolytic action of
3alpha,5alpha TH PROG (Akwa et al., 1999).
Fluctuations in plasma or brain concentrations of 3alpha,5alpha
THPROG, occurring in associationwith specific physiological and
pathological conditions, such as stress, pregnancy, the menstrual
cycle, menopause, regulation of neuronal excitability, and a variety
of neurological or psychiatric disorders (Barbaccia et al., 1996;
Bicikova et al., 1998; Concas et al., 1998; Genazzani et al., 1998;
Biggio and Purdy, 2001) result in changes in neuronal excitability
and, in turn, in alteration of emotional state, sleep pattern, and
seizure threshold (Guidotti and Costa, 1998; Engel and Grant,
2001; Wang et al., 2001). Moreover, physiological or pharmaco-
logically induced changes in the levels of 3a,5a-TH PROG are
associated, at the molecular level, with changes in the
expression of GABAA receptor subunits (Biggio and Purdy,
2001; Biggio et al., 2001; Smith and Gong, 2004). Given that
3alpha,5alpha TH PROG and 3alpha,5alpha TH DOC are
among the most potent positivemodulators of GABAA receptor
Fig. 3. Effect of long-term treatment with progesterone on Y1R/LacZ transgene expression in the medial amygdala. Progesterone treatment was performed as described
in Fig. 2. Histochemical staining of β-galactosidase activity in coronal sections of the medial amygdala 90 min after the last injection is shown for mice treated with
vehicle (A) or with progesterone (5 mg/kg, i.p) (B), as well as for mice that received a single daily subcutaneous injection of finasteride (25 mg/kg) during the last week
of treatment with progesterone (C). Scale bar, 100 μm. Reproduced from Ferrara et al., J. Neurochem. 2001;79: 417–425 with permission of Blackwell Publishing.
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brain concentrations of these neuroactive steroids might also
affect Y1R gene expression in the amygdala.
Chronic treatment with progesterone or with 3alpha,5alpha
TH PROG induces a significant augmentation of the cerebro-
cortical concentration of 3alpha,5alpha TH PROG and
3alpha,5alpha TH DOC (Fig. 2) that is associated with an
increase in the expression of the Y1R/LacZ transgene in the MeAFig. 4. Quantitation of Y1R/LacZ transgene expression in the medial amygdala of
mice subjected to longterm treatment with progesterone or AP. (A) Mice were
subjected to prolonged treatment with vehicle (VEH), with progesterone (P), or
with progesterone and finasteride (P+F) as described in Fig. 2, and were killed
90 min (VEH, P, P+F) or 24 h (PW, PW+F) after the last injection (W indicates
withdrawal). Coronal sections of the medial amygdala were subjected to
quantitative analysis of β-galactosidase histochemical staining. Data are
expressed as the density of blue dots and are means±SEM of values from 5
to 15 mice. *p<0.01 versus VEH, PW, and P+F groups (Newman–Keuls test).
(B) Mice were treated for 10 days with vehicle or AP (5 mg/kg, i.p.) and were
killed 90 min (VEH, AP) or 24 h (APW) after the last injection. Data were
analyzed as in (A) and are means±SEM of values from 5 to 10 mice. *p<0.01,
**p<0.05 versus VEH (Newman–Keuls test). Reproduced from Ferrara et al.,
J. Neurochem. 2001;79: 417–425 with permission of Blackwell Publishing.similar to that elicited by long-term administration of abecarnil
or diazepam (Figs. 3A,B, 4) (Ferrara et al., 2001).
In addition, physiological fluctuations in the cerebrocortical
concentrations of endogenous 3alpha,5alpha TH PROG and
3alpha,5alpha TH DOC during pregnancy (Table 1) are also
associated with increased Y1R/LacZ transgene expression in the
MeA (Figs. 5A,B, 6) (Oberto et al., 2002). The levels of Y1R
mRNA in the MeAwere also increased on day 18 of pregnancy,
suggesting that changes in transgene expression reflect parallel
changes in the endogenous Y1R gene that are achieved, at least
in part, via transcriptional mechanisms (Fig. 7). The increase in
the Y1R gene expression in the MeA induced by chronic
treatment with progesterone or by physiological conditions,
such as pregnancy, is likely to be mediated by 3alpha,5alpha TH
PROG and 3alpha,5alpha TH DOC through their selective
action at the GABAA receptor. In fact, pretreatment of Y1R/LacZ
transgenic mice with the 5α-reductase inhibitor finasteride,
which inhibits the biosynthesis of 3alpha,5alpha TH PROG andTable 1
Effects of finasteride treatment on the concentrations of progesterone, AP, and
THDOC in the cerebral cortex of estrus and pregnant mice
Steroid (ng/g)
Progesterone AP THDOC
Estrus 15.8±1.7 11.6±0.8 3.6±0.5
Estrus+finasteride 16.5±3.0 9.4±1.4 3.9±0.1
Pregnant 39.8±2.8* 24.2±2.2** 9.9±1.3**
Pregnant+ finasteride 39.9±3.9* 15.8±1.9 4.5±0.4
Mice were treated with vehicle or finasteride (25 mg/kg, s.c.) from day 12 to day
17 of pregnancy and killed on day 18. Estrus mice were similarly treated with
finasteride or vehicle for 6 days. Data are means±SEM of values from 4 to 10
mice and are expressed as nanograms of steroid per gram of cortical tissue.
*p<0.01 versus estrus and estrus+ finasteride; **p<0.01 versus estrus, estrus+
finasteride, and pregnant+ finasteride (Newman–Keuls test). Reproduced from
Oberto et al., J. Neurochem. 2002;82: 1272-1281, with permission of Blackwell
Publishing.
Fig. 5. Effects of pregnancy and delivery on Y1R/LacZ transgene expression in
the medial amygdala. Coronal sections of the medial amygdala of mice in estrus
(A), on day 18 of pregnancy in the absence (B) or presence (C) of finasteride
treatment (25 mg/kg, s.c. from day 12 to day 17), or on day 2 after delivery (D)
were subjected to histochemical staining for β-galactosidase activity. Scale bar,
100 μm. Reproduced from Oberto et al., J. Neurochem. 2002;82: 1272–1281,
with permission of Blackwell Publishing.
Fig. 6. Quantitation of Y1R/LacZ transgene expression in the medial amygdala of
mice during pregnancy and after delivery. (A) Coronal sections of the medial
amygdala were subjected to quantitative analysis of β-galactosidase histochem-
ical staining. Values are shown for mice in estrus (E), on day 18 of pregnancy
(P18), and on days 2 (PD2) and 7 (PD7) after delivery. Data are expressed as the
density of blue dots and are means±SEM of values from 5 to 9 mice. *p<0.01
versus E, PD2, and PD7 (Newman–Keuls test). (B) Pregnant mice were injected
daily with vehicle or finasteride (25 mg/kg, s.c.) from day 12 to day 17 and then
killed on day 18 (P18 and P18+F, respectively). Estrus mice were similarly
treated with vehicle (VEH) or with finasteride (F) for 6 days. Coronal sections of
the medial 43 amygdala were then analyzed for β-galactosidase activity as in
(A). Data are means±SEM of values from 5 to 10 mice. *p<0.01 versus VEH,
F, and P18+F (Newman–Keuls test). Reproduced from Oberto et al., J.
Neurochem. 2002;82: 1272–1281, with permission of Blackwell Publishing.
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the accumulation of 3alpha,5alpha TH PROG and 3alpha,5al-
pha TH DOC in the cerebral cortex as well as the increase in
Y1R/LacZ gene expression in the amygdala (Ferrara et al., 2001;
Oberto et al., 2002). These findings therefore suggest that the
high concentrations achieved by neuroactive steroids in the
cerebral cortex of mice following chronic treatment with pro-
gesterone or during pregnancy might play a major role in
modulation of both GABAA and Y1R mediated transmissions.
Fluctuation in the levels of brain 3a,5a-TH PROG are asso-
ciated with alterations of the subunit composition of the GABAA
receptor as well as of GABAA receptor function (Biggio and
Purdy, 2001; Biggio et al., 2001; Smith and Gong, 2004; Follesa
et al., 2005; Serra et al., 2006); these changes might, in turn,
produce adaptive responses in the NPY-mediated transmission
and Y1R gene expression. Indeed, the reduction in the brain
concentrations of these steroids elicited either by a physiological
condition (delivery) or by pharmacological treatment (finaster-
ide) reversed or prevented both the increase in Y1R/LacZ trans-
gene expression (Ferrara et al., 2001; Oberto et al., 2002) as well
as changes in the expression of GABAA receptor subunit genes
(Biggio et al., 2001). The rapid decrease in the 3alpha,5alpha TH
PROG and 3alpha,5alpha TH DOC cerebrocortical concentra-tions, following discontinuation of chronic progesterone
administration (Fig. 2) as well as following delivery, induce
withdrawal effects at the behavioural and molecular levels that
are highly similar to those elicited by discontinuation of long-
term treatment with positive allosteric modulators of GABAA
receptor such as benzodiazepines (Follesa et al., 1998, 2001).
However, the increase of Y1R/LacZ transgene expression in the
MeA was no longer apparent 24 h after the last hormone
injection, or after delivery, indicating that changes in NPY-Y1R
signal do not play a role in progesterone-induced withdrawal
syndrome (Figs. 4, 5D, 6A).
6.2. Effects of chronic voluntary alcohol consumption and
ethanol withdrawal on Y1R gene expression in the amygdala
Ethanol exerts anxiolytic, sedative/hypnotic, anticonvulsant,
and muscle relaxant effects similar to those induced by different
modulators of the GABAA receptor such as benzodiazepines,
barbiturates, and neuroactive steroids (Brot et al., 1995; Grobin
et al., 1998;Koob et al., 1998;VanDoren et al., 2000). Behavioural,
neurochemical, and electrophysiological evidences indicate that
GABAA receptors are indeed targets for the acute as well as
chronic actions of ethanol. The acute action of ethanol is charac-
terized by a facilitation of GABAA receptor function, whereas, on
the contrary, its chronic exposure is associated to a diminished
sensitivity to GABA, benzodiazepines and barbiturates, and to an
enhanced sensitivity to neuroactive steroids and to the inverse
agonists at the benzodiazepine receptors β-carbolines (Mhatre
Fig. 7. Effects of pregnancy on Y1 receptor mRNA expression in the medial
amygdala. Low power magnification of an autoradiogram illustrating the
neuroanatomical distribution of Y1 receptor mRNA visualized by in situ
hybridization on a coronal brain section from an estrous female mice (A). Scale
bar, 1 mm. High power magnification of autoradiograms showing the right
medial amygdala of female mice in estrus (B) and on day 18 of pregnancy (C).
Original sections were hybridized with four oligonucleotide probes and exposed
to X-ray film for 8 days. The figure is representative of results obtained from 4 to
6 mice in each group. Scale bar, 0.5 mm. Reproduced from Oberto et al.,
J. Neurochem. 2002;82: 1272–1281, with permission of Blackwell Publishing.
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et al., 1996).
Moreover, long-term administration of ethanol and ethanol
withdrawal elicit neurochemical and molecular effects similar to
those induced by positive modulators of GABAA receptor func-
tion (Morrow et al., 1990; Mhatre et al., 1993; Devaud et al.,
1997; Biggio et al., 2003). In particular, chronic ethanol admin-
istration differentially alters the expression of distinct GABAA
receptor subunit mRNA and peptides in various brain regions
(Mhatre and Ticku, 1992; Devaud et al., 1997; Sanna et al., 2003;
Follesa et al., 2005; Olsen et al., 2005).
In addition to a direct action at the GABAA receptor, the acute
action of ethanol at GABAA receptors was proposed to be
mediated by neuroactive steroids produced in peripheral organs,
or by peripheral precursors that are converted to neurosteroids
by brain cells (Morrow et al., 1999). Acute ethanol administra-
tion increases the concentrations of allopregnanolone in the
plasma, cerebral cortex, and hippocampus (Barbaccia et al.,
1999; VanDoren et al., 2000; Morrow et al., 2001; Serra et al.,
2003). Furthermore, pretreatment of animals with the 5α-
reductase inhibitor finasteride, reduced the ethanol-induced
increase in the cerebrocortical concentrations of 3alpha,5alpha
TH PROG and prevented certain molecular, neurochemical,
electrophysiological, and behavioural effects of ethanol (Van-
Doren et al., 2000; Khisti et al., 2002).
NPY is also involved with neurobiological responses to
ethanol (Thiele and Badia-Elder, 2003; Pandey, 2003; Koob,2003; Thiele et al., 2004). Voluntary alcohol consumption and
resistance to the intoxicating effects of ethanol are inversely
related to NPY levels in knockout and transgenic mice. NPY
knockout mice consume significantly higher amounts of ethanol
than do wild type strains, whereas transgenic mice over ex-
pressing NPY have a lower preference for ethanol than wild type
mice (Thiele et al., 1998). Chronic ethanol administration and
ethanol withdrawal also influence NPY signalling, although the
effect of ethanol on NPY may vary with the duration and type of
ethanol treatment, rodent strain and brain region. For instance,
both investigator- and self-administered ethanol increases NPY
levels in the hypothalamic structures and in ventrolateral medulla
of Long Evans rats (Clark et al., 1998) whereas no differences in
NPY protein content were observed in several brain regions of
Wistar rats following 7 week exposure to ethanol vapours (Ehlers
et al., 1998) or in Sprague Dawley rats fed for 15 days with
ethanol diet (Roy and Pandey, 2002). Conversely, NPY im-
munoreactivity and NPY mRNAwere shown to be decreased by
single or repeated administrations of intoxicating doses of ethanol
in distinct brain regions of rodents, including the hypothalamus,
hippocampus and cerebral cortex (Kinoshita et al., 2000; Roy and
Pandey, 2002; Bison and Crews, 2003).
On the other hand, consistent results have found that NPY
levels and mRNA are significantly decreased 24 h after with-
drawal in some brain regions involved in seizure activity and
anxious behaviour, including CeA, MeA, cerebral cortex and
hippocampus (Roy and Pandey, 2002; Zhang and Pandey, 2003;
Bison and Crews, 2003), suggesting that a reduced activity of
NPY neurons may represent one of the mechanisms implicated in
ethanol withdrawal symptoms. This decrease is followed by a
dramatic increase of NPY expression in the hippocampus that
occurs 72 h after withdrawal which was suggested to represent a
protective response against prolonged withdrawal seizure activity
(Ehlers et al., 1998; Bison and Crews, 2003).
We demonstrated that Y1R gene expression in the MeA and
CeA of Y1R/LacZ transgenic mice was not affected by voluntary
alcohol consumption for 4 weeks, but it significantly increased
48 h following ethanol withdrawal (Mele et al., submitted for
publication). This finding suggests the possibility that the
decrease of NPY levels in the amygdaloid structures, that is
associated with the behavioural manifestations of ethanol with-
drawal, may induce the up-regulation of the Y1R subtype.
To determinewhether the increased biosynthesis of 3alpha,5al-
pha TH PROG induced by ethanol was responsible for its effect
on Y1R gene transcriptional activity we analyzed the effect of
pretreatment with finasteride of Y1R/LacZ transgenic mice on β-
galactosidase expression in the CeA and MeA. Our findings
demonstrated that finasteride administration prevented both the
ethanolinduced increase of 3alpha,5alpha TH PROG in the
cerebral cortex as well as the increase of Y1R/LacZ gene ex-
pression in the amygdala induced by 24 h ethanol withdrawal in
the amygdala (Mele et al., submitted for publication). These
findings suggest that the ability of ethanol withdrawal to affect the
NPY-Y1R signal transmission involves fluctuation of brain
concentrations of 3alpha,5alpha TH PROG and may possibly
depend on changes of GABAA receptor function and subunit
composition that occur during ethanol consumption and ethanol
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LacZ transgene expression induced by ethanol withdrawal,
finasteride pretreatment reduces ethanol withdrawal severity
(Finn et al., 2004; Gorin et al., 2005).
6.3. Effect of a transient increase of cerebrocortical concen-
trations of neuroactive steroids on Y1R gene expression in the
amygdala of Y1R/LacZ transgenic mice?
NPY and GABA may also interact to inhibit the excitatory
effects of CRF in the amygdala and thereby contribute to the
overall response to stressful or threatening stimuli (Heilig et al.,
1994). Several acute stress paradigms, such as forced
swimming, foot shock, and carbon dioxide inhalation, reduce
GABAA receptor function in several brain regions, induce
proconflict behavior (Corda and Biggio, 1986) and increase the
concentrations of neuroactive steroids in plasma and the brain to
levels that are high enough to activate GABAA receptors (Purdy
et al., 1991; Barbaccia et al., 1996, 1997, 2001; Reddy and
Rogawski, 2002). The rapid and persistent increase in
neuroactive steroid concentrations induced by acute stress has
been proposed to represent a homeostatic mechanism for the
restoration of GABAA receptor function and to be physiolog-
ically relevant in protection against stress-induced seizures. On
the other hand, short-term physical restraint, which induces
anxiety, reduces NPY mRNA and protein concentrations in the
amygdala and cortex of rats (Thorsell et al., 1998). In contrast,
repeated exposure to restraint once daily for 10 days increases
NPY expression in the amygdala and in the ARC (Thorsell et
al., 1999).
Given that the sustained increase of cerebrocortical
concentrations of neuroactive steroids that occurs during
pregnancy or long-term administration of progesterone affect
both GABAA receptor and Y1R gene expression (Concas et al.,
1998; Follesa et al., 1998; Ferrara et al., 2001; Oberto et al.,
2002), we have examined the hypothesis that a rapid increase
in the plasma and brain content of these compounds might also
participate in the regulation of Y1R plasticity in response to
restraint stress.
Acute exposure to restraint induced a transient increase in
the cerebrocortical concentrations of neuroactive steroids that
returns to control values within 30 min. Acute restraint also
increased Y1R/LacZ transgene expression in the CeA and in the
MeA of transgenic mice (Mele et al., 2004). Finasteride
prevented the transient increase in the cerebrocortical con-
centrations of 3alpha,5alpha-TH PROG and 3alpha,5alpha-TH
DOC, but failed to inhibit that in Y1R gene expression in the
amygdala of the stressed mice. Moreover, repeated exposure to
restraint, that induces repetitive and transient elevation in the
concentrations of neuroactive steroids in the cerebral cortex,
failed to affect Y1R gene (Mele et al., 2004). These finding,
taken together, indicate that changes in the brain concentra-
tions of neuroactive steroids and in Y1R gene expression
induced by restraint stress are achieved independently of each
other and suggest that a sustained increase in the brain
concentrations of these steroids may be required for modula-
tion of Y1R gene expression.Accordingly, the exposure to 5 min foot shock stress as
well as the acute treatment with ethanol, both of which
transiently increase the concentrations of 3alpha,5alpha-TH
PROG in the cerebral cortex, failed to affect Y1R in transgenic
mice (unpublished results).
7. Conclusions
Results reviewed above indicate that chronic administration
of various modulators of the GABAA receptor complex as well
as prolonged pharmacologically or physiologically induced
changes in 3alpha,5alpha-TH PROG concentrations affect Y1R
gene expression in the MeA and CeA.
Molecular, physiological and neurochemical evidence dem-
onstrated that long term exposure to these modulators triggers
cellular adaptive mechanisms that involve alteration in the
subunit composition of the GABAA receptor with regional
differences which, in turn, might affect receptor function and
altered pharmacological and behavioural sensitivity (Follesa et
al., 2000, 2001, 2002).
Given the important role of the GABA/NPY interaction in
regulation of several functions, including emotional behaviour
and neuronal excitability, these findings suggest that altered
GABA receptor function might trigger compensatory changes
on NPY-containing neurons that, in turn, might be responsible
of up-regulation of Y1R gene. This hypothesis is supported by
the observation that chronic treatment with benzodiazepines
modulates the expression of NPY and NPY mRNA in various
brain regions (Krysiak et al., 1999, 2000). Furthermore the
decrease of GABAA receptor γ2 subunit expression induced by
the administration of antisense oligonucleotides is associated
with a profound increase of NPY mRNA and receptor protein
expression in rat hippocampus (Mikkelsen et al., 2001).
On the other hand, we have shown that fluctuations in the
cerebrocortical concentration of 3alpha,5alpha- THPROGduring
voluntary ethanol consumption and ethanol withdrawal induces a
marked increase in Y1 receptor gene expression that becomes
apparent 48 h after withdrawal. This observation suggests that the
increase of brain neuroactive steroid concentrations induced by
voluntary ethanol consumption might produce changes on
GABAA receptor function different from those induced by pro-
gesterone treatment or pregnancy. In this regard, ethanol has been
shown to increase brain steroidogenesis by a local action inde-
pendently on the activity of the hypothalamicpituitary-adrenal
axis (Sanna et al., 2004). Given the diversity and heterogeneity of
GABAA receptor expressed in different neurons the ethanol-
induced changes in the expression of each subunit might dif-
ferently affect the NPY-Y1 pathway.
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